Trial Profile
A multicentre randomised phase III study of low-dose thalidomide, prednisolone and zoledronic acid versus prednisolone and zoledronic acid to assess survival post-ASCT maintenance therapy in patients with multiple myeloma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Jul 2016
Price :
$35
*
At a glance
- Drugs Thalidomide (Primary) ; Prednisolone; Zoledronic acid
- Indications Multiple myeloma
- Focus Therapeutic Use
- Sponsors Amgen
- 01 Jul 2016 New trial record